Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 250 entries
View as:

A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05292898 Org: User:
Start: 03/14/22 End: 03/31/25 Due: 03/31/26

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Phase: N/A Priority: Normal
NCT ID: NCT04034446 Org: User:
Start: 09/30/19 End: 12/01/20 Due: 12/01/21

A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities

Phase: N/A Priority: Normal
NCT ID: NCT05850286 Org: User:
Start: 04/20/23 End: 04/30/27 Due: 04/30/28

Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05941585 Org: User:
Start: 08/08/23 End: 01/17/25 Due: 01/17/26

Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL

Phase: N/A Priority: Normal
NCT ID: NCT05594784 Org: User:
Start: 10/08/22 End: 03/25/25 Due: 03/25/26

Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT06770257 Org: User:
Start: 12/10/25 End: 06/10/27 Due: 06/10/28

VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT

Phase: N/A Priority: Normal
NCT ID: NCT06447090 Org: User:
Start: 04/12/24 End: 10/31/27 Due: 10/31/28

Efficacy of Venetoclax Combined with Intensive Chemotherapy in Different Subgroups of AML

Phase: N/A Priority: Normal
NCT ID: NCT06635681 Org: User:
Start: 09/29/24 End: 10/01/28 Due: 10/01/29

Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06265545 Org: User:
Start: 02/22/24 End: 06/30/26 Due: 06/30/27

Efficacy and Safety of Avatrombopag vs. Avatrombopag Combined With rhTPO in the Treatment of SAA

Phase: N/A Priority: Normal
NCT ID: NCT06254287 Org: User:
Start: 02/01/24 End: 12/31/24 Due: 12/31/25

The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.

Phase: N/A Priority: Normal
NCT ID: NCT05630651 Org: User:
Start: 04/19/23 End: 12/31/28 Due: 12/31/29

Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the Elderly

Phase: N/A Priority: Normal
NCT ID: NCT05433922 Org: User:
Start: 06/01/22 End: 12/31/24 Due: 12/31/25

Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04067414 Org: User:
Start: 06/14/18 End: 12/31/20 Due: 12/31/21

Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05660473 Org: User:
Start: 10/31/22 End: 12/30/27 Due: 12/30/28

Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04415008 Org: User:
Start: 06/01/20 End: 06/01/27 Due: 06/01/28

Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT06449482 Org: User:
Start: 05/05/23 End: 03/30/25 Due: 03/30/26

Low-dose Cyclophosphamide or CNI in the Prevention of Acute Graft-versus-host Disease After gDLI

Phase: N/A Priority: Normal
NCT ID: NCT06490562 Org: User:
Start: 07/31/24 End: 12/31/28 Due: 12/31/29

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05987696 Org: User:
Start: 08/10/23 End: 08/31/26 Due: 08/31/27

Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05318963 Org: User:
Start: 03/14/22 End: 03/31/25 Due: 03/31/26

A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06880354 Org: User:
Start: 05/22/25 End: 03/31/28 Due: 03/31/29

A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL

Phase: N/A Priority: Normal
NCT ID: NCT03980002 Org: User:
Start: 05/15/19 End: 12/30/27 Due: 12/30/28

The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

Phase: N/A Priority: Normal
NCT ID: NCT06021977 Org: User:
Start: 09/01/23 End: 12/31/25 Due: 12/31/26

National Longitudinal Cohort of Hematological Diseases (NICHE) - CART

Phase: N/A Priority: Normal
NCT ID: NCT06607289 Org: User:
Start: 06/01/21 End: 12/31/32 Due: 12/31/33

Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06996132 Org: User:
Start: 05/09/25 End: 12/30/27 Due: 12/30/28

National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT07019766 Org: User:
Start: 01/01/00 End: 12/31/70 Due: 12/31/71